Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067321 | 1.00 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL5557385 | 1.00 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL5861676 | 1.00 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL2768845 | 1.00 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL3842695 | 0.96 | TK2 (0.33) | TK2TK1 | |
| SCHEMBL26869 | 0.94 | TK2 (0.33) | TK2TK1 | |
| SCHEMBL4087414 | 0.90 | — | — | |
| SCHEMBL1408601 | 0.90 | — | — | |
| SCHEMBL2230744 | 0.90 | TK1 (0.31) | TK1 | |
| SCHEMBL19815618 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | claimed |
| US-20030144231-A1 | Oligonucleotide analogues | EXIQON A/S (DK) | 2003-07-31 | — | — | US | claimed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | claimed |
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2002-06-06 | — | — | US | claimed |
| EP-4709857-A1 | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE | Astrazeneca AB (SE) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231559-A1 | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | WO | disclosed |
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-1499578-A2 | PRIME RING SUBSTITUTED THYROID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIAC AND METABOLIC DISORDERS | KARO BIO AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030144231-A1 | Oligonucleotide analogues | EXIQON A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| WO-2003018515-A2 | PRIME RING SUBSTITUTED THYROID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIAC AND METABOLIC DISORDERS | KARO BIO AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| US-20030032794-A1 | Method for preparation of LNA phosphoramidites | SANTARIS PHARMA A/S (DK) | 2003-02-13 | — | — | US | disclosed |
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032794-A1 | Method for preparation of LNA phosphoramidites | NCL, PNP, RNGTT | TK2 175/4885TK1 37/4885 |
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | DCLRE1B, TARBP1, NCL | TK2 26/4885TK1 9/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | TK2 25/4885TK1 7/4885 |
| US-20030144231-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | TK2 25/4885TK1 7/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | TK2 55/4885TK1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.